Euronext's gene therapy debut

GenSight Biologics S.A. (Euronext:SIGHT) got out on Euronext thanks in part to investors wanting to own the first European-listed gene therapy company. But it might have to wait for a late 2017 data event before it is valued in line with its closest U.S. comparator.

Last week GenSight raised €40 million ($44.1 million) in an IPO through the sale of 5 million shares at €8, for a postmoney valuation of €148.9 million ($164.2 million). ...